Clinical Trials Browser

Phase 1/2 × INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Clear all

NCT06353386 2026-05-26

MK-5684-01A

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Phase 1/2 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04868604 2026-05-06

SECuRE

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07258407 2026-03-16

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms, Castration-Resistant

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Recruiting

GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Phase 1/2 Withdrawn

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant